Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial

JACC: Heart Failure

Volumn 4, Issue 7, 2016, Pages 521-535

  Bristow, Michael R ^a   Saxon, Leslie A ^b   Feldman, Arthur M ^c   Mei, Chaoqun ^d   Anderson, Susan A ^d   DeMets, David L ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Biventricular pacing; Cardiac resynchronization therapy; Chronic heart failure; Implantable cardiac defibrillator; Intraventricular conduction delays

Indexed keywords

BIVENTRICULAR ASSIST DEVICE; CARDIAC RESYNCHRONIZATION THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; AGED; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CHRONIC DISEASE; FEMALE; HEART STROKE VOLUME; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; CHRONIC DISEASE; DEFIBRILLATORS, IMPLANTABLE; DIURETICS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84975679549     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.02.019     Document Type: Review

References (55)

1. Bristow M.R., Saxon L.A., Boehmer J., et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
2. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L. for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
3. Unverferth D.V., Magorien R.D., Moeschberger M.L., Baker P.B., Fetters J.K., Leier C.V. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984, 54:147-152.
4. Shamim W., Francis D.P., Yousufuddin M., Varney S., Pieopli M.F., Anker S.D. Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J Cardiol 1999, 70:171-178.
5. Cazeau S., Ritter P., Lazarus A., et al. First experience in treatment of terminal cardiac insufficiency using multisite stimulation. Bull Acad Natl Med 1996, 180:2065-2075.
6. Blanc J.J., Etienne Y., Gilard M., et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. Circulation 1997, 96:3273-3277.
7. Kass D.A., Chen C.H., Curry C., et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999, 99:1567-1573.
8. Alonso C., Leclercq C., Victor F., et al. Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure. Am J Cardiol 1999, 84:1417-1421.
9. Kerwin W.F., Botvinick E.H., O'Connell J.W., et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol 2000, 35:1221-1227.
10. Nelson G.S., Berger R.D., Fetics B.J., et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000, 102:3053-3059.
11. Saxon L.A., Boehmer J.P., Hummel J., et al. Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. Am J Cardiol 1999, 83(Suppl):120D-123D. for the VIGOR CHF and VENTAK CHF Investigators.
12. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873-880.
13. Abraham W.T., Fisher W.G., Smith A.L., et al. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346:1845-1853.
14. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933-1940. for the Multicenter Automatic Defibrillator Implantation Trial Investigators.
15. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883. for the Multicenter Automatic Defibrillator Implantation Trial II Investigators.
16. Bristow M.R., Feldman A.M., Saxon L.A. Heart failure management using implantable devices for intraventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. J Card Fail 2000, 6:276-285.
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Code of Federal Regulations. Title 21, Volume 1, Part 50-protection of human subjects; Subpart B-informed consent of human subjects. April 1, 2003.
18. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
19. Harrington D., Fleming T. Counting Processes and Survival Analysis (Wiley Series in Probability and Statistics) 1991, John Wiley, New York.
20. Lan K.K.G., DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
21. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
22. U.S. Food and Drug Administration. Medtronic® InSync® Biventricular Pacing System including the InSync® Model 8040 Pulse Generator, Attain™ LV Model 2187 and Attain™ CS Model 2188 Leads-P010015. Available at: . Accessed September 4, 2015. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm085388.htm.
23. U.S. Food and Drug Administration. Guidant Cardiac Resynchronization Therapy Defibrillator System including the CONTAK CD® pulse generator and the EASYTRAK® left ventricular coronary venous lead-P010012. Available at: . Accessed September 4, 2015. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm083475.htm.
24. U.S. Food and Drug Administration. Medtronic® InSync® ICD Model 7272 Dual Chamber Implantable Cardioverter Defibrillator System with Cardiac Resynchronization Therapy-P010031. Available at: . Accessed September 4, 2015. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm083428.htm.
25. Bunnik E.M., Janssens A.C., Schermer M.H. A tiered-layered-staged model for informed consent in personal genome testing. Eur J Hum Genet 2013, 21:596-601.
26. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361:1329-1338.
27. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
28. MERIT Steering Committee and Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
29. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000, 283:1295-1302. for the MERIT-HF Study Group.
30. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
31. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.
32. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717. for the Randomized Aldactone Evaluation Study Investigators.
33. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
34. Hayes D.L., Boehmer J.P., Day J.D., et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011, 8:1469-1475.
35. Carson P., Anand I., O'Connor C., et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005, 46:2329-2334.
36. Feldman A.M., de Lissovoy G., Bristow M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005, 46:2311-2321.
37. Hurst T.M., Hinrichs M., Breidenbach C., Katz N., Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999, 34:402-408.
38. Powell B.D., Saxon L.A., Boehmer J.P., et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE Survival by Rhythm Study. J Am Coll Cardiol 2013, 62:1674-1679.
39. Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. Circulation 2006, 114:2766-2772.
40. Wolinsky F.D., Smith D.M., Stump T.E., Overhage J.M., Lubitz R.M. The sequelae of hospitalization for congestive heart failure among older adults. J Am Geriatr Soc 1997, 45:558-563.
41. Khand A.U., Gemmell I., Rankin A.C., Cleland J.G. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J 2001, 22:153-164.
42. Beshai J.F., Grimm R.A., Nagueh S.F., et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007, 357:2461-2471.
43. Ruschitzka F., Abraham W.T., Singh J.P., et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013, 369:1395-1405.
44. Fiuzat M., O'Connor C.M., Gueyffier F., et al. Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail 2013, 19:592-599.
45. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996, 94:2285-2296.
46. St.John Sutton M.G., Plappert T., Abraham W.T., et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107:1985-1990.
47. Mann D.L., Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005, 111:2837-2849.
48. Iyengar S., Haas G., Lamba S., et al. Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. J Card Fail 2007, 13:304-311.
49. Vanderheyden M., Mullens W., Delrue L., et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 2008, 51:129-136.
50. Martens P., Verbrugge F.H., Mullens W. Optimizing CRT-do we need more leads and delivery methods. J Atr Fib 2015, 7:39-47.
51. Alternate Site Cardiac Resynchronization (ALSYNC) Study (ALSYNC). Available at: . Accessed October 7, 2015. https://clinicaltrials.gov/ct2/show/NCT01277783.
52. U.S. Food and Drug Administration. Summary of safety and effectiveness. Available at: . Accessed February 5, 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf/P010012S026b.pdf.
53. Hunter NL. FDA announces first-ever patient engagement advisory committee. Available at: . Accessed February 11, 2016. http://blogs.fda.gov/fdavoice/index.php/2015/09/fda-announces-first-ever-patient-engagement-advisory-committee/.
54. Freidlin B., Korn E.L., Gray R., Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res 2008, 14:4368-4371.
55. Parmar M.K., Carpenter J., Sydes M.R. More multiarm randomised trials of superiority are needed. Lancet 2014, 384:283-284.